Business Description
Molecular Templates Inc
NAICS : 325414
SIC : 2836
ISIN : US6085501095
Description
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.94 | |||||
| Equity-to-Asset | 0.12 | |||||
| Debt-to-Equity | 2.9 | |||||
| Debt-to-EBITDA | 10.51 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -16.76 | |||||
| Beneish M-Score | 3.41 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 33.4 | |||||
| 3-Year EPS without NRI Growth Rate | 56.6 | |||||
| 3-Year FCF Growth Rate | 31.2 | |||||
| 3-Year Book Growth Rate | -64.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.15 | |||||
| 9-Day RSI | 37.55 | |||||
| 14-Day RSI | 35.08 | |||||
| 6-1 Month Momentum % | -60.92 | |||||
| 12-1 Month Momentum % | -61.42 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.97 | |||||
| Quick Ratio | 0.97 | |||||
| Cash Ratio | 0.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.3 | |||||
| Shareholder Yield % | 245.59 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -19.89 | |||||
| Net Margin % | -15.44 | |||||
| FCF Margin % | -79.85 | |||||
| ROA % | -13.96 | |||||
| ROIC % | -22.23 | |||||
| ROC (Joel Greenblatt) % | -26.26 | |||||
| ROCE % | -19.82 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.13 | |||||
| PB Ratio | 2.19 | |||||
| Price-to-Tangible-Book | 2.19 | |||||
| EV-to-EBIT | -2.05 | |||||
| EV-to-EBITDA | 9.66 | |||||
| EV-to-Revenue | 0.21 | |||||
| EV-to-Forward-Revenue | 1.27 | |||||
| EV-to-FCF | -0.27 | |||||
| Earnings Yield (Greenblatt) % | -48.78 | |||||
| FCF Yield % | -374.28 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers